BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

831 related articles for article (PubMed ID: 25345091)

  • 1. Mucopolysaccharidosis type I.
    Wraith JE; Jones S
    Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():102-6. PubMed ID: 25345091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Residual α-L-iduronidase activity in fibroblasts of mild to severe Mucopolysaccharidosis type I patients.
    Oussoren E; Keulemans J; van Diggelen OP; Oemardien LF; Timmermans RG; van der Ploeg AT; Ruijter GJ
    Mol Genet Metab; 2013 Aug; 109(4):377-81. PubMed ID: 23786846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enzyme replacement therapy with laronidase (Aldurazyme(®)) for treating mucopolysaccharidosis type I.
    Jameson E; Jones S; Remmington T
    Cochrane Database Syst Rev; 2016 Apr; 4():CD009354. PubMed ID: 27033167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enzyme replacement therapy in mucopolysaccharidosis type I: progress and emerging difficulties.
    Wraith JE
    J Inherit Metab Dis; 2001 Apr; 24(2):245-50. PubMed ID: 11405343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enzyme replacement therapy with laronidase (Aldurazyme) for treating mucopolysaccharidosis type I.
    Jameson E; Jones S; Wraith JE
    Cochrane Database Syst Rev; 2013 Sep; (9):CD009354. PubMed ID: 24085657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enzyme-replacement therapy in a 5-month-old boy with attenuated presymptomatic MPS I: 5-year follow-up.
    Gabrielli O; Clarke LA; Bruni S; Coppa GV
    Pediatrics; 2010 Jan; 125(1):e183-7. PubMed ID: 20026495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hurler syndrome: early diagnosis and treatment].
    Leroux S; Muller JB; Boutaric E; Busnel A; Lemouel F; Andro-Garçon M; Neven B; Valayannopoulos V; Vinceslas C
    Arch Pediatr; 2014 May; 21(5):501-6. PubMed ID: 24698225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined enzyme replacement and haematopoietic stem cell transplantation in Hurler syndrome.
    Bijarnia S; Shaw P; Vimpani A; Smith R; Pacey V; O'Grady H; Christodoulou J; Sillence D
    J Paediatr Child Health; 2009; 45(7-8):469-72. PubMed ID: 19712183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzyme replacement therapy with laronidase (Aldurazyme(®)) for treating mucopolysaccharidosis type I.
    Jameson E; Jones S; Wraith JE
    Cochrane Database Syst Rev; 2013 Nov; (11):CD009354. PubMed ID: 24257962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Mucopolysaccharidosis I, Hurler syndrome: a case report].
    Amorín M; Carlin A; Prötzel A
    Arch Argent Pediatr; 2012 Oct; 110(5):e103-6. PubMed ID: 23070190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hematopoietic stem cell transplantation effects on spinal cord compression in Hurler.
    Ferrara G; Maximova N; Zennaro F; Gregori M; Tamaro P
    Pediatr Transplant; 2014 May; 18(3):E96-9. PubMed ID: 24483599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of enzyme replacement and hematopoietic stem cell transplantation as therapy for Hurler syndrome.
    Tolar J; Grewal SS; Bjoraker KJ; Whitley CB; Shapiro EG; Charnas L; Orchard PJ
    Bone Marrow Transplant; 2008 Mar; 41(6):531-5. PubMed ID: 18037941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzyme replacement therapy with laronidase (Aldurazyme
    Jameson E; Jones S; Remmington T
    Cochrane Database Syst Rev; 2019 Jun; 6(6):CD009354. PubMed ID: 31211405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Open issues in Mucopolysaccharidosis type I-Hurler.
    Parini R; Deodato F; Di Rocco M; Lanino E; Locatelli F; Messina C; Rovelli A; Scarpa M
    Orphanet J Rare Dis; 2017 Jun; 12(1):112. PubMed ID: 28619065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosing lysosomal storage disorders: mucopolysaccharidosis type I.
    Johnson BA; Dajnoki A; Bodamer OA
    Curr Protoc Hum Genet; 2015 Jan; 84():17.17.1-17.17.8. PubMed ID: 25599668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progressive eye pathology in mucopolysaccharidosis type I mice and effects of enzyme replacement therapy.
    Gonzalez EA; Visioli F; Pasqualim G; de Souza CFM; Marinho DR; Giugliani R; Matte U; Baldo G
    Clin Exp Ophthalmol; 2020 Apr; 48(3):334-342. PubMed ID: 31925897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The MPS I registry: design, methodology, and early findings of a global disease registry for monitoring patients with Mucopolysaccharidosis Type I.
    Pastores GM; Arn P; Beck M; Clarke JT; Guffon N; Kaplan P; Muenzer J; Norato DY; Shapiro E; Thomas J; Viskochil D; Wraith JE
    Mol Genet Metab; 2007 May; 91(1):37-47. PubMed ID: 17336562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The development of cognitive functions in children with Hurler phenotype mucopolysaccharidosis type I on enzyme replacement therapy with laronidase].
    Biernacka M; Jakubowska-Winecka A; Tylki-Szymańska A
    Pediatr Endocrinol Diabetes Metab; 2010; 16(4):249-54. PubMed ID: 21447265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Scheie syndrome: enzyme replacement therapy does not prevent progression of cervical myelopathy due to spinal cord compression.
    Illsinger S; Lücke T; Hartmann H; Mengel E; Müller-Forell W; Donnerstag F; Das AM
    J Inherit Metab Dis; 2009 Dec; 32 Suppl 1():S321-5. PubMed ID: 19894140
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 42.